Galapagos NV Logo

Galapagos NV

ISIN: BE0003818359 | Ticker: GLPG | LEI: 549300QKJ78IY0IOV655
Sector: Health CareSub-Industry: Biotechnology
Country: Belgium

About Galapagos NV

Company Description

We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Year founded


Served area



Generaal De Wittelaan L11 A3, 2800 Mechelen, Antwerpen – Belgium

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
21.12.23 Guenter Peter Board Buy EUR 23,069.75
21.12.23 Baker Daniel George Board Buy EUR 22,736.24
21.12.23 Schaffert Susanne Antonie Board Buy EUR 12,896.14
21.12.23 Sturge Simon John Board Buy EUR 6,448.07
28.08.23 Manto Michele Board Buy EUR 0.00
25.08.23 Missotten Annelies Board Buy EUR 89,284.00
07.07.23 Missotten Annelies Board Buy EUR 0.00
08.05.23 Stoffels IMC Board Buy EUR 0.00
06.05.23 Filius Bart Board Other EUR 51,662.16
06.05.23 Manto Michele Board Other EUR 21,774.96

Short Interest

Current short interest

Position Holder Short Interest in Percent Date
Qube Research & Technologies Ltd. 0.50% 18.09.23
Arrowstreet Capital, Limited Partnership 0.51% 27.04.23
Total 1.01%

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Euronext Brussels

Stock Index


Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.